Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://www.cardiologyres.org

Original Article

Volume 15, Number 3, June 2024, pages 189-197

Selection Criteria in the Era of Perfect Competition for Drug-Eluting Stents in Association With Operator Volumes: An Operator-Volume Analysis of the Selection DES Study

Figure 1. The main results of Table 2. This figure represents the current drug-eluting stent market share in Japan where CoCr-EES was selected by more than 70% of respondents in different operator volumes in > 20% of their percutaneous coronary intervention (PCI) procedures. On the other hand, UPF-SES, BCS, and DTS were less likely to be selected, indicating that more than 70% of respondents select < 5% of these in their procedures. The percentage of selection by low-, intermediate-, and high-volume operators among the DESs used demonstrated no difference, except for DTS. CoCr-EES: Abbott’s Xience™ cobalt chromium everolimus-eluting stent; PtCr-EES: Boston Scientific’s Synergy™ platinum chromium everolimus-eluting stent; ZES: Medtronic’s Resolute Onyx™ zotarolimus-eluting stent; BP-SES: Terumo’s Ultimaster™ sirolimus-eluting stent with bioresorbable polymer; BCS: Biosensors’s BioFreedom™ biolimus-coated stent; UPF-SES: B.antibody-coated Combo^® ISAR Neo sirolimus-eluting stent; DTS: OrbusNeich’s dual-therapy sirolimus-eluting and CD34⁺ antibody-coated Combo^® stent.

**Table 1.** Backgrounds of the Study Participant
	Total	Low (< 50 PCIs/yr)	Intermediate (50 - 100 PCIs/yr)	High (> 100 PCIs/yr)	P value
PCI: percutaneous coronary intervention; yr: year.
Operator volume	126	49 (38.9)	47 (37.3)	30 (23.8)
Hospital types
University Hospital	21 (16.7)	8 (16.3)	9 (19.1)	4 (13.3)	0.011
Public General-City Hospital	31 (24.6)	19 (38.8)	11 (23.4)	1 (3.3)
Private General-City Hospital	65 (51.6)	21 (42.9)	22 (46.8)	22 (73.3)
Cardiovascular Center	9 (7.1)	1 (2.0)	5 (10.6)	3 (10.0)
Age distribution
Less than 31	6 (4.8)	1 (2.0)	1 (2.1)	4 (13.3)	0.267
31 - 40	44 (34.9)	20 (40.8)	17 (36.2)	7 (23.3)
41 - 50	24 (19.0)	10 (20.4)	10 (21.3)	4 (13.3)
51 - 60	39 (31.0)	14 (28.6)	13 (27.7)	12 (40.0)
More than 60	13 (10.3)	4 (8.2)	6 (12.8)	3 (10.0)
Hospital annual PCI volume
Less than 21	2 (1.6)	2 (4.1)	0 (0)	0 (0)	< 0.001
21 - 50	4 (3.2)	3 (6.1)	1 (2.1)	0 (0)
51 - 100	11 (8.7)	9 (18.4)	2 (4.3)	0 (0)
101 - 200	22 (17.5)	14 (28.6)	3 (6.4)	5 (16.7)
More than 200	87 (69.0)	21 (42.9)	41 (87.2)	25 (83.3)
Hospital annual emergent/urgent PCI volume
Less than 21	11 (8.7)	8 (16.3)	2 (4.3)	1 (3.3)	< 0.001
21 - 50	26 (20.6)	19 (38.8)	4 (8.5)	3 (10.0)
51 - 100	48 (38.1)	15 (30.6)	22 (46.8)	11 (36.7)
101 - 200	27 (21.4)	6 (12.2)	14 (29.8)	7 (23.3)
More than 200	14 (11.1)	1 (2.0)	5 (10.6)	8 (26.7)
Operator's PCI experience
Less than 5 yrs	16 (12.7)	11 (22.4)	2 (4.3)	3 (10.0)	0.122
5 - 10 yrs	25 (19.8)	9 (18.4)	13 (27.7)	3 (10.0)
11 - 20 yrs	57 (45.2)	18 (36.7)	23 (48.9)	16 (53.3)
21 - 30 yrs	26 (20.6)	11 (22.4)	8 (17.0)	7 (23.1)
More than 30 yrs	2 (1.6)	0 (0)	1 (2.1)	1 (3.3)
Position at the hospital
President/vice president	14 (11.1)	4 (8.2)	4 (8.5)	6 (20.0)	0.745
Director	39 (31.0)	14 (28.6)	17 (36.2)	8 (26.7)
Manager	33 (26.2)	13 (26.5)	12 (25.5)	8 (26.7)
Staff	37 (29.4)	16 (32.7)	13 (27.7)	8 (26.7)
Others	3 (2.4)	2 (4.1)	1 (2.1)	0 (0)
Device selection right
PCI operator	103 (81.7)	41 (83.7)	39 (83.0)	23 (76.7)	0.789
Director/manager of the division	14 (11.1)	6 (12.2)	4 (8.5)	4 (13.3)
Device dependent	9 (7.1)	2 (4.1)	4 (8.5)	3 (10.0)

Table 1. Backgrounds of the Study Participant

Total

Low (< 50 PCIs/yr)

Intermediate (50 - 100 PCIs/yr)

High (> 100 PCIs/yr)

P value

PCI: percutaneous coronary intervention; yr: year.

Operator volume

126

49 (38.9)

47 (37.3)

30 (23.8)

Hospital types

University Hospital

21 (16.7)

8 (16.3)

9 (19.1)

4 (13.3)

0.011

Public General-City Hospital

31 (24.6)

19 (38.8)

11 (23.4)

1 (3.3)

Private General-City Hospital

65 (51.6)

21 (42.9)

22 (46.8)

22 (73.3)

Cardiovascular Center

9 (7.1)

1 (2.0)

5 (10.6)

3 (10.0)

Age distribution

Less than 31

6 (4.8)

1 (2.0)

1 (2.1)

4 (13.3)

0.267

31 - 40

44 (34.9)

20 (40.8)

17 (36.2)

7 (23.3)

41 - 50

24 (19.0)

10 (20.4)

10 (21.3)

4 (13.3)

51 - 60

39 (31.0)

14 (28.6)

13 (27.7)

12 (40.0)

More than 60

13 (10.3)

4 (8.2)

6 (12.8)

3 (10.0)

Hospital annual PCI volume

Less than 21

2 (1.6)

2 (4.1)

0 (0)

< 0.001

21 - 50

4 (3.2)

3 (6.1)

1 (2.1)

0 (0)

51 - 100

11 (8.7)

9 (18.4)

2 (4.3)

0 (0)

101 - 200

22 (17.5)

14 (28.6)

3 (6.4)

5 (16.7)

More than 200

87 (69.0)

21 (42.9)

41 (87.2)

25 (83.3)

Hospital annual emergent/urgent PCI volume

Less than 21

11 (8.7)

8 (16.3)

2 (4.3)

1 (3.3)

< 0.001

21 - 50

26 (20.6)

19 (38.8)

4 (8.5)

3 (10.0)

51 - 100

48 (38.1)

15 (30.6)

22 (46.8)

11 (36.7)

101 - 200

27 (21.4)

6 (12.2)

14 (29.8)

7 (23.3)

More than 200

14 (11.1)

1 (2.0)

5 (10.6)

8 (26.7)

Operator's PCI experience

Less than 5 yrs

16 (12.7)

11 (22.4)

2 (4.3)

3 (10.0)

0.122

5 - 10 yrs

25 (19.8)

9 (18.4)

13 (27.7)

3 (10.0)

11 - 20 yrs

57 (45.2)

18 (36.7)

23 (48.9)

16 (53.3)

21 - 30 yrs

26 (20.6)

11 (22.4)

8 (17.0)

7 (23.1)

More than 30 yrs

2 (1.6)

0 (0)

1 (2.1)

1 (3.3)

Position at the hospital

President/vice president

14 (11.1)

4 (8.2)

4 (8.5)

6 (20.0)

0.745

Director

39 (31.0)

14 (28.6)

17 (36.2)

8 (26.7)

Manager

33 (26.2)

13 (26.5)

12 (25.5)

8 (26.7)

Staff

37 (29.4)

16 (32.7)

13 (27.7)

8 (26.7)

Others

3 (2.4)

2 (4.1)

1 (2.1)

0 (0)

Device selection right

PCI operator

103 (81.7)

41 (83.7)

39 (83.0)

23 (76.7)

0.789

Director/manager of the division

14 (11.1)

6 (12.2)

4 (8.5)

4 (13.3)

Device dependent

9 (7.1)

2 (4.1)

4 (8.5)

3 (10.0)

**Table 2.** The Use of Drug-Eluting Stent Rate in Relation to the Operator Volume
	Total	Low (< 50 PCIs/yr)	Intermediate (50 - 100 PCIs/yr)	High (> 100 PCIs/yr)	P value
The vertical column indicates the proportion of brand DES that the operator uses in practice. Low = less than 5%; Medium = 5-20%; High = more than 20%. DES: drug-eluting stent; CoCr-EES: Abbott’s Xience™ cobalt chromium everolimus-eluting stent; PtCr-EES: Boston Scientific’s Synergy™ platinum chromium everolimus-eluting stent; ZES: Medtronic’s Resolute Onyx™ zotarolimus-eluting stent; BP-SES: Terumo’s Ultimaster™ sirolimus-eluting stent with bioresorbable polymer; BCS: Biosensors’s BioFreedom™ biolimus-coated stent; UPF-SES: B.Braun’s Coroflex® ISAR Neo sirolimus-eluting stent; DTS: OrbusNeich’s dual-therapy sirolimus-eluting and CD34+ antibody-coated Combo® stent; yr: year.
CoCr-EES	126	49	47	30
Low (< 5% use)	11 (8.7)	5 (10.2)	3 (6.4)	3 (10.0)	0.941
Medium (5-20% use)	26 (20.6)	11 (22.4)	9 (19.1)	6 (20.0)
High (> 20% use)	89 (70.6)	33 (67.3)	35 (74.5)	21 (70.0)
PtCr-EES	126	49	47	30
Low (< 5% use)	31 (24.6)	11 (22.4)	15 (31.9)	5 (16.7)	0.563
Medium (5-20% use)	46 (36.5)	17 (34.7)	17 (36.2)	12 (40.0)
High (> 20% use)	49 (38.9)	21 (42.9)	15 (31.9)	13 (43.3)
ZES	126	49	47	30
Low (< 5% use)	45 (35.7)	22 (44.9)	16 (34.0)	7 (23.3)	0.192
Medium (5-20% use)	51 (40.5)	17 (34.7)	22 (46.8)	12 (40.0)
High (> 20% use)	30 (23.8)	10 (20.4)	9 (19.1)	11 (36.7)
BP-SES	126	49	47	30
Low (< 5% use)	39 (31.0)	17 (34.7)	13 (27.7)	9 (30.0)	0.954
Medium (5-20% use)	47 (37.3)	17 (34.7)	18 (38.3)	12 (40.0)
High (> 20% use)	40 (31.7)	15 (30.6)	16 (34.0)	9 (30.0)
UPF-SES	126	49	47	30
Low (< 5% use)	99 (78.6)	41 (83.7)	34 (72.3)	24 (80.0)	0.623
Medium (5-20% use)	20 (15.9)	5 (10.2)	10 (21.3)	5 (16.7)
High (> 20% use)	7 (5.6)	3 (6.1)	3 (6.4)	1 (3.3)
BCS	126	49	47	30
Low (< 5% use)	110 (87.3)	46 (93.9)	40 (85.1)	24 (80.0)	0.349
Medium (5-20% use)	12 (9.5)	3 (6.1)	5 (10.6)	4 (13.3)
High (> 20% use)	4 (3.2)	0 (0)	2 (4.3)	2 (6.7)
DTS	126	49	47	30
Low (< 5% use)	105 (83.3)	47 (95.9)	37 (78.7)	21 (70.0)	0.009
Medium (5-20% use)	16 (12.7)	2 (4.1)	6 (12.8)	8 (26.7)
High (> 20% use)	5 (4.0)	0 (0)	4 (8.5)	1 (3.3)

Table 2. The Use of Drug-Eluting Stent Rate in Relation to the Operator Volume

Total

Low (< 50 PCIs/yr)

Intermediate (50 - 100 PCIs/yr)

High (> 100 PCIs/yr)

P value

The vertical column indicates the proportion of brand DES that the operator uses in practice. Low = less than 5%; Medium = 5-20%; High = more than 20%. DES: drug-eluting stent; CoCr-EES: Abbott’s Xience™ cobalt chromium everolimus-eluting stent; PtCr-EES: Boston Scientific’s Synergy™ platinum chromium everolimus-eluting stent; ZES: Medtronic’s Resolute Onyx™ zotarolimus-eluting stent; BP-SES: Terumo’s Ultimaster™ sirolimus-eluting stent with bioresorbable polymer; BCS: Biosensors’s BioFreedom™ biolimus-coated stent; UPF-SES: B.Braun’s Coroflex® ISAR Neo sirolimus-eluting stent; DTS: OrbusNeich’s dual-therapy sirolimus-eluting and CD34+ antibody-coated Combo® stent; yr: year.

CoCr-EES

126

Low (< 5% use)

11 (8.7)

5 (10.2)

3 (6.4)

3 (10.0)

0.941

Medium (5-20% use)

26 (20.6)

11 (22.4)

9 (19.1)

6 (20.0)

High (> 20% use)

89 (70.6)

33 (67.3)

35 (74.5)

21 (70.0)

PtCr-EES

126

Low (< 5% use)

31 (24.6)

11 (22.4)

15 (31.9)

5 (16.7)

0.563

Medium (5-20% use)

46 (36.5)

17 (34.7)

17 (36.2)

12 (40.0)

High (> 20% use)

49 (38.9)

21 (42.9)

15 (31.9)

13 (43.3)

ZES

126

Low (< 5% use)

45 (35.7)

22 (44.9)

16 (34.0)

7 (23.3)

0.192

Medium (5-20% use)

51 (40.5)

17 (34.7)

22 (46.8)

12 (40.0)

High (> 20% use)

30 (23.8)

10 (20.4)

9 (19.1)

11 (36.7)

BP-SES

126

Low (< 5% use)

39 (31.0)

17 (34.7)

13 (27.7)

9 (30.0)

0.954

Medium (5-20% use)

47 (37.3)

17 (34.7)

18 (38.3)

12 (40.0)

High (> 20% use)

40 (31.7)

15 (30.6)

16 (34.0)

9 (30.0)

UPF-SES

126

Low (< 5% use)

99 (78.6)

41 (83.7)

34 (72.3)

24 (80.0)

0.623

Medium (5-20% use)

20 (15.9)

5 (10.2)

10 (21.3)

5 (16.7)

High (> 20% use)

7 (5.6)

3 (6.1)

3 (6.4)

1 (3.3)

BCS

126

Low (< 5% use)

110 (87.3)

46 (93.9)

40 (85.1)

24 (80.0)

0.349

Medium (5-20% use)

12 (9.5)

3 (6.1)

5 (10.6)

4 (13.3)

High (> 20% use)

4 (3.2)

0 (0)

2 (4.3)

2 (6.7)

DTS

126

Low (< 5% use)

105 (83.3)

47 (95.9)

37 (78.7)

21 (70.0)

0.009

Medium (5-20% use)

16 (12.7)

2 (4.1)

6 (12.8)

8 (26.7)

High (> 20% use)

5 (4.0)

0 (0)

4 (8.5)

1 (3.3)

**Table 3.** Internal and External Factors that Affect the Different Operator Volume
Classifications	Variables that affect DES selection criteria	Low-volume operator	Intermediate-volume operator	High-volume operator
CoCr-EES: Abbott’s Xience™ cobalt chromium everolimus-eluting stent; PtCr-EES: Boston Scientific’s Synergy™ platinum chromium everolimus-eluting stent; ZES: Medtronic’s Resolute Onyx™ zotarolimus-eluting stent; BP-SES: Terumo’s Ultimaster™ sirolimus-eluting stent with bioresorbable polymer; BCS: Biosensors’s BioFreedom™ biolimus-coated stent; UPF-SES: B.Braun’s Coroflex^® ISAR Neo sirolimus-eluting stent; DTS: OrbusNeich’s dual-therapy sirolimus-eluting and CD34⁺ antibody-coated Combo^® stent.
Overall devise selection criteria	Evidence focus	0.365	0.109	1.223	0.102	1.933	0.711	5.256	0.197	1.156	0.311	4.297	0.828
	Product performance/ease of use	2.631	0.866	7.988	0.088	0.549	0.211	1.428	0.219	0.812	0.228	2.889	0.748
	User experience	0.941	0.398	2.223	0.889	1.931	0.811	4.596	0.137	0.412	0.141	1.201	0.104
	Patient/lesion background	1.158	0.414	3.241	0.779	0.644	0.269	1.543	0.323	1.946	0.638	5.939	0.242
	Personal relationship with company/sales representative	0.402	0.175	0.922	0.031	1.161	0.61	2.206	0.65	2.218	0.863	5.7	0.098
	DES brand	1.032	0.418	2.547	0.945	0.884	0.435	1.796	0.733	1.183	0.399	3.507	0.762
	Size availability	0.619	0.237	1.614	0.326	1.162	0.513	2.632	0.719	2.157	0.624	7.46	0.225
	Order from superiors/peers	1.187	0.665	2.119	0.562	0.94	0.576	1.533	0.803	1.013	0.507	2.023	0.972
DES types	CoCr-EES	0.732	0.488	1.1	0.133	1.074	0.759	1.52	0.685	1.25	0.772	2.024	0.363
	PtCr-EES	1.123	0.781	1.614	0.532	0.733	0.543	0.991	0.044	1.098	0.745	1.62	0.637
	ZES	0.689	0.48	0.989	0.043	0.966	0.705	1.325	0.831	1.768	1.131	2.766	0.012
	BP-SES	0.755	0.513	1.112	0.155	1.092	0.782	1.525	0.605	1.218	0.783	1.895	0.381
	UPF-SES	1.337	0.797	2.242	0.271	1.102	0.722	1.682	0.654	0.437	0.205	0.931	0.032
	BCS	0.562	0.264	1.194	0.134	0.901	0.523	1.553	0.708	1.48	0.747	2.931	0.261
	DTS	0.361	0.175	0.744	0.006	1.604	1.026	2.507	0.038	1.363	0.782	2.374	0.274
Expectations from DES company	Provision of data	0.691	0.259	1.849	0.462	1.518	0.545	4.225	0.425	0.827	0.247	2.768	0.758
	Research and development	2.777	0.75	10.282	0.126	0.491	0.176	1.37	0.174	0.74	0.153	3.579	0.708
	Provision of product information	1.276	0.395	4.128	0.684	0.633	0.197	2.038	0.444	1.26	0.276	5.757	0.766
	After sales services	0.703	0.267	1.848	0.474	1.559	0.672	3.613	0.301	1.031	0.304	3.499	0.961
	More activity support	1.824	0.751	4.432	0.184	0.736	0.355	1.525	0.409	1.126	0.407	3.117	0.819
Lesion affecting DES selection	Chronic total occlusion	1.355	0.589	3.118	0.475	0.848	0.409	1.757	0.658	0.886	0.342	2.295	0.803
	Calcification	1.133	0.485	2.65	0.773	1.64	0.766	3.507	0.203	0.478	0.17	1.347	0.162
	Left-main bifurcation	1.819	0.737	4.489	0.195	0.936	0.395	2.221	0.881	0.386	0.111	1.342	0.134
	Bending	0.339	0.123	0.938	0.037	1.815	0.736	4.474	0.195	1.796	0.552	5.839	0.33
	Small vessel	0.853	0.345	2.111	0.731	0.721	0.321	1.621	0.429	2.816	0.8	9.912	0.107
	Restenosis	0.797	0.382	1.662	0.545	0.897	0.468	1.722	0.745	1.912	0.737	4.963	0.183
Patient background influencing DES selection	Patient age	1.786	0.789	4.044	0.164	0.854	0.429	1.696	0.651	0.63	0.263	1.51	0.3
	Diabetes	1.004	0.355	2.84	0.994	0.843	0.357	1.991	0.697	1.658	0.488	5.636	0.418
	Dialysis	1.326	0.476	3.692	0.589	1.053	0.449	2.472	0.906	0.432	0.127	1.474	0.18
	High bleeding risk	1.805	0.668	4.874	0.244	1.161	0.487	2.765	0.736	0.564	0.17	1.878	0.351
	Schedule for surgery	1.096	0.494	2.433	0.822	0.725	0.343	1.533	0.4	1.443	0.485	4.298	0.51
	Acute coronary syndrome	0.637	0.306	1.329	0.23	0.891	0.472	1.685	0.723	1.739	0.732	4.134	0.21

Table 3. Internal and External Factors that Affect the Different Operator Volume

Classifications

Variables that affect DES selection criteria

Low-volume operator

Intermediate-volume operator

High-volume operator

95% CI

P value

95% CI

P value

95% CI

P value

Lower

Upper

Lower

Upper

Lower

Upper

CoCr-EES: Abbott’s Xience™ cobalt chromium everolimus-eluting stent; PtCr-EES: Boston Scientific’s Synergy™ platinum chromium everolimus-eluting stent; ZES: Medtronic’s Resolute Onyx™ zotarolimus-eluting stent; BP-SES: Terumo’s Ultimaster™ sirolimus-eluting stent with bioresorbable polymer; BCS: Biosensors’s BioFreedom™ biolimus-coated stent; UPF-SES: B.Braun’s Coroflex^® ISAR Neo sirolimus-eluting stent; DTS: OrbusNeich’s dual-therapy sirolimus-eluting and CD34⁺ antibody-coated Combo^® stent.

Overall devise selection criteria

Evidence focus

0.365

0.109

1.223

0.102

1.933

0.711

5.256

0.197

1.156

0.311

4.297

0.828

Product performance/ease of use

2.631

0.866

7.988

0.088

0.549

0.211

1.428

0.219

0.812

0.228

2.889

0.748

User experience

0.941

0.398

2.223

0.889

1.931

0.811

4.596

0.137

0.412

0.141

1.201

0.104

Patient/lesion background

1.158

0.414

3.241

0.779

0.644

0.269

1.543

0.323

1.946

0.638

5.939

0.242

Personal relationship with company/sales representative

0.402

0.175

0.922

0.031

1.161

0.61

2.206

0.65

2.218

0.863

5.7

0.098

DES brand

1.032

0.418

2.547

0.945

0.884

0.435

1.796

0.733

1.183

0.399

3.507

0.762

Size availability

0.619

0.237

1.614

0.326

1.162

0.513

2.632

0.719

2.157

0.624

7.46

0.225

Order from superiors/peers

1.187

0.665

2.119

0.562

0.94

0.576

1.533

0.803

1.013

0.507

2.023

0.972

DES types

CoCr-EES

0.732

0.488

1.1

0.133

1.074

0.759

1.52

0.685

1.25

0.772

2.024

0.363

PtCr-EES

1.123

0.781

1.614

0.532

0.733

0.543

0.991

0.044

1.098

0.745

1.62

0.637

ZES

0.689

0.48

0.989

0.043

0.966

0.705

1.325

0.831

1.768

1.131

2.766

0.012

BP-SES

0.755

0.513

1.112

0.155

1.092

0.782

1.525

0.605

1.218

0.783

1.895

0.381

UPF-SES

1.337

0.797

2.242

0.271

1.102

0.722

1.682

0.654

0.437

0.205

0.931

0.032

BCS

0.562

0.264

1.194

0.134

0.901

0.523

1.553

0.708

1.48

0.747

2.931

0.261

DTS

0.361

0.175

0.744

0.006

1.604

1.026

2.507

0.038

1.363

0.782

2.374

0.274

Expectations from DES company

Provision of data

0.691

0.259

1.849

0.462

1.518

0.545

4.225

0.425

0.827

0.247

2.768

0.758

Research and development

2.777

0.75

10.282

0.126

0.491

0.176

1.37

0.174

0.74

0.153

3.579

0.708

Provision of product information

1.276

0.395

4.128

0.684

0.633

0.197

2.038

0.444

1.26

0.276

5.757

0.766

After sales services

0.703

0.267

1.848

0.474

1.559

0.672

3.613

0.301

1.031

0.304

3.499

0.961

More activity support

1.824

0.751

4.432

0.184

0.736

0.355

1.525

0.409

1.126

0.407

3.117

0.819

Lesion affecting DES selection

Chronic total occlusion

1.355

0.589

3.118

0.475

0.848

0.409

1.757

0.658

0.886

0.342

2.295

0.803

Calcification

1.133

0.485

2.65

0.773

1.64

0.766

3.507

0.203

0.478

0.17

1.347

0.162

Left-main bifurcation

1.819

0.737

4.489

0.195

0.936

0.395

2.221

0.881

0.386

0.111

1.342

0.134

Bending

0.339

0.123

0.938

0.037

1.815

0.736

4.474

0.195

1.796

0.552

5.839

0.33

Small vessel

0.853

0.345

2.111

0.731

0.721

0.321

1.621

0.429

2.816

0.8

9.912

0.107

Restenosis

0.797

0.382

1.662

0.545

0.897

0.468

1.722

0.745

1.912

0.737

4.963

0.183

Patient background influencing DES selection

Patient age

1.786

0.789

4.044

0.164

0.854

0.429

1.696

0.651

0.63

0.263

1.51

0.3

Diabetes

1.004

0.355

2.84

0.994

0.843

0.357

1.991

0.697

1.658

0.488

5.636

0.418

Dialysis

1.326

0.476

3.692

0.589

1.053

0.449

2.472

0.906

0.432

0.127

1.474

0.18

High bleeding risk

1.805

0.668

4.874

0.244

1.161

0.487

2.765

0.736

0.564

0.17

1.878

0.351

Schedule for surgery

1.096

0.494

2.433

0.822

0.725

0.343

1.533

0.4

1.443

0.485

4.298

0.51

Acute coronary syndrome

0.637

0.306

1.329

0.23

0.891

0.472

1.685

0.723

1.739

0.732

4.134

0.21